Authors

1. Schmit , Tammy L.
2. Pike , Marsha L.
3. Tulledge-Scheitel , Sidna M.
4. Fischer , Erin N.
5. Zhao , Yanjun
6. Hirn , Sarah L.
7. Kriewall , Nicole E.
8. Kudrna , Cory

Abstract

Our management strategies efficiently and safely provided treatment to more than 60% of patients at high risk of disease progression who would otherwise have been excluded from receiving this medication option due to drug-to-drug interactions with nirmatrelvir/ritonavir.